http://wakodiagnostics.com/

Contact Information:

Cindy Mays
Cell:  (818) 371-1799
cynthia.mays@fujifilm.com

Sean Ryan
Cell: (650)0390-4908
sean.ryan@fujifilm.com

Zoom Link

Sept. 11:

• 10:30 - 10:45 a.m. (break)
• 12 - 12:30 p.m. (break)
• 3 - 3:15 p.m. (break)
• 5 - 5:30 p.m. (adjournment)

Sept. 12:

• 9:40 - 9:55 a.m. (break)
• 11:35 - 11:55 a.m. (break)
• 1:40 - 2 p.m. (adjournment)

Virtual Exhibit Hall Home

FUJIFILM Wako Diagnostics U.S.A. Corporation
FUJIFILM Wako Diagnostics U.S.A., previously Wako Life Sciences, Inc. is focused on developing and providing high quality In vitro Diagnostic and Life Science products to our valued customers. With a commitment to the future of science, our company is dedicated to creating customer value and contentment as a supplier of innovative, technological solutions.

HCC Risk Biomarkers AFP-L3 and DCP
Wako's HCC risk biomarkers AFP-L3 and DCP are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of HCC.

The serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) have been shown to be specific to hepatocellular carcinoma (HCC) and their combined use aids in clinical assessment for early detection. Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now in the United States and Canada.

HCC Surveillance Improves Patient Outcome
Early detection of HCC is crucial for the application of curative therapies and improving patient outcome. HCC surveillance is a widely recommended practice for early detection of HCC.

The incidence of HCC is increasing worldwide. HCC is the second leading cause of cancer related death in the world. It is the fifth leading cause of cancer for men and the ninth for women [1].

At-risk patients for HCC development are highly encouraged to enroll in HCC surveillance programs for early detection of HCC. The American Association for the Study of Liver Diseases (AASLD) identifies patients with cirrhosis and patients with chronic hepatitis B infection (even if without cirrhosis) as being at high risk for HCC development [2].

Early detection of HCC is crucial for the application of curative therapies and improving patient outcome. HCC surveillance improves long-term, tumor-free survival of HCC patients receiving early treatment [3].

HCC Risk Biomarkers AFP-L3 and DCP Info and Ordering Information